CLARA CAMPÀS MOYA

Clara Campàs Moya stands as a pivotal figure in the European venture capital landscape, particularly within the dynamic life sciences and health technology sectors. As a Managing Partner and co-founder of Asabys Partners, she plays a crucial role in identifying, funding, and nurturing groundbreaking companies poised to revolutionize healthcare.

At Asabys Partners, Clara Campàs Moya's responsibilities extend across the entire investment lifecycle. She is instrumental in shaping the firm's strategic direction, leading investment committees, and overseeing portfolio management. Her deep scientific understanding, combined with sharp business acumen, allows her to evaluate complex technologies and market opportunities with precision. Asabys Partners, under her leadership, is dedicated to investing in innovative companies across life sciences, biotech, health tech, and digital health. This includes areas such as novel therapeutics, advanced diagnostics, innovative medical devices, and transformative digital health solutions designed to improve patient outcomes and healthcare efficiency.

Clara's career background is marked by a unique blend of scientific rigor and entrepreneurial drive. Holding a PhD in Pharmacy, her foundational expertise is rooted in scientific research and development. Prior to co-founding Asabys Partners, she gained significant operational experience in the biotech industry, notably serving as the CEO of Minoryx Therapeutics. This leadership role provided her with invaluable insights into the challenges and opportunities of scaling a biotech company from early development through clinical stages. Her journey from the laboratory to the boardroom exemplifies her comprehensive understanding of the entire innovation ecosystem, from scientific discovery to commercialization.

Throughout her career, Clara Campàs Moya has demonstrated a profound commitment to fostering innovation that addresses unmet medical needs. Her strategic vision and hands-on approach have been instrumental in the success of numerous ventures. While specific individual investments are often part of a broader fund strategy, her influence is evident in Asabys Partners' robust portfolio, which includes companies developing cutting-edge treatments for rare diseases, advanced diagnostic tools, and digital platforms enhancing patient care. Her work not only drives financial returns but also contributes significantly to advancing global health, solidifying her reputation as a leading investor and thought leader in the life sciences venture capital space.